Pseudomonas aeruginosa susceptible only to colistin in intensive care unit patients

Surgical Infections

Volumn 9, Issue 2, 2008, Pages 153-160

  Mastoraki, Aikaterini ^a   Douka, Evangelia ^a   Kriaras, Ioannis ^a   Stravopodis, Georgios ^a   Manoli, Heleni ^a   Geroulanos, Stefanos ^a  

^a ONASSIS CARDIAC SURGERY CENTER   (Greece)

Author keywords

[No Author keywords available]

Indexed keywords

COLISTIN;

ADULT; AGED; ARTICLE; ARTIFICIAL VENTILATION; CONTROLLED STUDY; FEMALE; GRAM NEGATIVE INFECTION; HUMAN; INTENSIVE CARE UNIT; MAJOR CLINICAL STUDY; MALE; MULTIDRUG RESISTANCE; MULTIPLE ORGAN FAILURE; POSTOPERATIVE INFECTION; PRIORITY JOURNAL; PSEUDOMONAS AERUGINOSA; VENTILATOR ASSOCIATED PNEUMONIA;

ADULT; AGED; AGED, 80 AND OVER; ANTI-BACTERIAL AGENTS; CARDIAC SURGICAL PROCEDURES; COLISTIN; DRUG RESISTANCE, MULTIPLE, BACTERIAL; FEMALE; HUMANS; INTENSIVE CARE UNITS; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; PSEUDOMONAS AERUGINOSA; PSEUDOMONAS INFECTIONS;

EID: 42449131306     PISSN: 10962964     EISSN: None     Source Type: Journal    
DOI: 10.1089/sur.2007.004     Document Type: Article

References (31)

1. Vincent JL. Microbial resistance: Lessons from the EPIC study. European Prevalence of Infection. Intensive Care Med 2000;26:S3-S8.
2. Vincent JL, Bihari DJ, Suter PM, et al. The prevalence of nosocomial infection in intensive care units in Europe: Results of the European Prevalence of Infection in Intensive Care (EPIC) Study. EPIC International Advisory Committee. JAMA 1995;274:639-644.
3. Catchpole CR, Andrews JM, Brenwald N, Wise R. A reassessment of the in vitro activity of colistin sulphomethate sodium. J Antimicrob Chemother 1997;39:255-260.
4. Li J, Turnidge J, Milne R, Nation RL, et al. In vitro pharmacodynamic properties of colistin and colistin methanesulfonate against Pseudomonas aeruginosa isolates from patients with cystic fibrosis. Antimicrob Agents Chemother 2001;45:781-785.
5. Garnacho-Montero J, Ortiz-Leyba C, Jimenez-Jimenez FJ, et al. Treatment of multidrug-resistant Acinetobacter baumannii ventilator-associated pneumonia (VAP) with intravenous colistin: A comparison with imipenem-susceptible VAP. Clin Infect Dis 2003;36:1111-1118.
6. Levin AS, Baron AA, Penco J et al. Intravenous colistin as therapy for nosocomial infections caused by multidrug resistant Pseudomonas aeruginosa and Acinetobacter baumannii. Clin Infect Dis 1999;28:1008-1011.
7. Ouderkirk JP, Nord JA, Turett GS, Kislak JW. Polymyxin B nephrotoxicity and efficacy against nosocomial infections caused by multiresistant gram-negative bacteria. Antimicrob Agents Chemother 2003;47:2659-2662.
8. National Committee for Clinical Laboratory Standards. Methods for Dilution Antimicrobial Susceptibility Test for Bacteria that Grow Aerobically. Fifth edition. Approved Standard M7-A5. National Committee for Clinical Laboratory Standards, Wayne, PA. 2002.
9. Soussy CJ, Carret G, Cavallo JD, et al. Comite de l'antibiogramme de la Société Française de Microbiologie. Bulletin 2000-2001. Pathol Biol 2000;48:832-871.
10. Gaynes RP, Horan TC. Surveillance of nosocomial infections. Appendix A. CDC definitions of nosocomial infections. In: Mayhall CG, ed. Hospital Epidemiology and Infection Control. Baltimore. Williams and Wilkins 1996:1-14.
11. Girlich D, Poirel L, Leelaporn A, et al. Molecular epidemiology of the integron-located VEB-1 extended-spectrum beta-lactamase in nosocomial enterobacterial isolates in Bangkok, Thailand. J Clin Microbiol 2001;39:175-182.
12. Hocquet D, Bertrand X, Kohler T, et al. Genetic and phenotypic variations of a resistant Pseudomonas aeruginosa epidemic clone. Antimicrob Agents Chemother 2003;47:1887-1894.
13. Poirel L, Menuteau O, Agoli N, et al. Outbreak of extended-spectrum beta-lactamase VEB-1-producing isolates of Acinetobacter baumannii in a French hospital. J Clin Microbiol 2003;41:3542-3547.
14. Livermore DM. β-Lactamases of Pseudomonas aeruginosa. Antibiot Chemother 1991;44:215-220.
15. Nordmann P, Guibert M. Extended-spectrum betalactamases in Pseudomonas aeruginosa. J Antimicrob Chemother 1998;42:128-131.
16. Lodge JM, Minchin SD, Piddock LJ, Busby JW. Cloning, sequencing and analysis of the structural gene and regulatory region of the Pseudomonas aeruginosa chromosomal ampC beta-lactamase. Biochem J 1990;272:627-631.
17. Trias J, Nikaido H. Outer membrane protein D2 catalyzes facilitated diffusion of carbapenems and penems through the outer membrane of Pseudomonas aeruginosa. Antimicrob Agents Chemother 1990;34:52-57.
18. Livermore DM. Interplay of impermeability and chromosomal beta-lactamase activity in imipenem-resistant Pseudomonas aeruginosa. Antimicrob Agents Chemother 1992;36:2046-2048.
19. Poirel L, Naas T, Nicolas D, et al. Characterization of VIM-2, a carbapenem-hydrolyzing metallo-beta-lactamase and its plasmid- and integron-borne gene from a Pseudomonas aeruginosa clinical isolate in France. Antimicrob Agents Chemother 2000;44:891-897.
20. Dubois V, Aprin C, Melon M, et al. Nosocomial outbreak due to a multiresistant strain of Pseudomonas aeruginosa P-12: Efficacy cefepime-amikacin therapy and analysis of β-lactam resistance. J Clin Microbiol 2001;39:2072-2078.
21. Horton J, Pankey GA. Polymyxin B, colistin and sodium colistimethate. Med Clin North Am 1982;66:135-142.
22. Hancock REW, Chapple DS. Peptide antibiotics. Antimicrob Agents Chemother 1999;43:1317-1323.
23. Evans ME, Feola DJ, Rapp RP: Polymyxin B sulfate and colistin: Old antibiotics for emerging multiresistant gram-negative bacteria. Ann Pharmacother 1999;33:960-967.
24. Goodwin N. Colistin and sodium colistimethate. Med Clin North Am 1970;54:1267-1276.
25. Koch-Weser J, Sidel VW, Federman EB, et al. Adverse effects of sodium colistimethate. Ann Intern Med 1970;72:857-868.
26. Bosso JA, Liptak CA, Seilheimer DK, Harrison GM. Toxicity of colistin in cystic fibrosis patients. Ann Pharmacother 1991;25:1168-1170.
27. Ledson MJ, Galagher MJ, Cowperthwaite C, et al. Four years' experience of intravenous colomycin in an adult cystic fibrosis unit. Eur Respir J 1998;12:592-594.
28. Clermont G, Acker CG, Angus DC, et al. Renal failure in the ICU: Comparison of the impact of acute renal failure and end-stage renal failure on ICU outcomes. Kidney Int 2002;62:986-996.
29. Rynn C, Wooton M, Bowker KE, et al. In vitro assessment of colistin's antipseudomonal antimicrobial interactions with other antibiotics. Clin Microbiol Infect 1999;5:32-36.
30. Falagas ME, Rafailidis PI, Kasiakou SK, et al. Effectiveness and nephrotoxicity of colistin monotherapy vs. colistin-meropenem combination therapy for multidrug-resistant gram-negative bacterial infections. Clin Microbiol Infect 2006;12:1227-1230.
31. Linden PK, Paterson DL. Parenteral and inhaled colistin for treatment of ventilator-associated pneumonia. Clin Infect Dis 2006;43:89-94.